oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Upcoming Events
-
Investor Days Thüringen 2022
14. June - 15. June -
Vulvovaginal Disease Update (ISSVD)
15. July - 16. September -
XXVI World Congress of the international Society for the Study of Vulvovaginal Disease (ISSVD)
18. July - 20. July
Contact
oncgnostics GmbH
BioInstrumentezentrum Jena
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
WHO recommends one-dose HPV vaccination for girls
BlogThe World Health Organisation (WHO) recommends the one-dose HPV vaccination of girls and women up to 21 years of age instead of the current two-time vaccination. The WHO wants to increase the vaccination rate in the fight against cervical cancer. In principle, we welcome this plan, but we also have reservations regarding the new recommendation[1]. […]
oncgnostics at EUROGIN 2022
BlogThe EUROGIN is THE event for our current application areas and most of the experts were in Düsseldorf. So were we! With four presentations oncgnostics participated in the scientific discourse at the International multidisciplinary HPV Congress. The congress was again a great opportunity for us to make new contacts, maintain existing partnerships and exchange ideas […]
Oncgnostics receives award: Germany’s most innovative companies
BlogThe business magazine Capital selected Germany’s most innovative companies for the third time. Oncgnostics GmbH made it into the selection. The biotech company scored particularly well in the evaluation criterion of innovation areas. For the third time, Capital, together with the market research institute Statista, determined Germany’s most innovative companies. For this purpose, they brought […]
A startup turns 10 – oncgnostics grows with its employees
Blog10 years ago a small, very motivated team founded the oncgnostics GmbH to improve cervical cancer screening. Since then, oncgnostics GmbH has been growing and with it the number of its employees. On the occasion of the anniversary, it is time to share the experiences of the employees of the biotech company. 10 years of […]
Cancer prevention remains a matter of the heart: Biotech company oncgnostics celebrates 10th anniversary
Press ReleasesThe company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in Europe and Asia. In addition, oncgnostics conducts research in the field of diagnostics for head and neck cancer. The company is growing steadily and has […]
Third Generation Sequencing: Detecting cancer at DNA level
BlogDr. Carolin Dippmann and Daria Meyer from our research and development team work, among other things, with the “third-generation sequencing” method. With the help of this technology, they are examining DNA (deoxyribonucleic acid) from tumors much more precisely than was previously possible. The method has enormous advantages: epigenetic changes in the DNA, specifically DNA methylation […]
That was 2021 – and here’s what happens next
BlogWe look back on the milestones of 2021 – and forward to upcoming projects. In May, we moved the entire company within Jena, thus gaining space for more office workspace and a better layout of the labs. Recently, our team grew by one colleague, so that we are now 18 people. One of the reasons […]
Ovarian cancer: The silent danger
BlogEvery year, about 7,300 women in Germany are diagnosed with ovarian cancer (ovarian carcinoma), and more than 5,000 die of the consequences. This means that one in 72 women will be diagnosed with ovarian cancer at some point in their lives. In those affected, cells on one or both ovaries change malignantly and begin to […]
Epigenetic markers – definition and significance for early cancer detection
BlogAs a biotechnology company, we have been researching cancer diagnostics on a molecular basis since 2012. We deal with epigenetic markers, which help us to recognise cancers, such as cervical cancer, in their preliminary stages. In this article, we explain the terms “epigenetics” and “epigenetic marker”. Epigenetics – what is it? Epigenetics deals with the […]
Pilot study: Cancer screening from home is possible
Press ReleasesA large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much less frequent since the onset of the corona pandemic. A study by Hannover Medical School and the biotechnology company oncgnostics GmbH is testing self-tests as […]